Coherus Historical Cash Flow

CHRS Stock  USD 1.09  0.01  0.91%   
Analysis of Coherus BioSciences cash flow over time is an excellent tool to project Coherus BioSciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 31.7 M or Begin Period Cash Flow of 60.8 M as it is a great indicator of Coherus BioSciences ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Coherus BioSciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Coherus BioSciences is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.

About Coherus Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Coherus balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Coherus's non-liquid assets can be easily converted into cash.

Coherus BioSciences Cash Flow Chart

At this time, Coherus BioSciences' Change In Cash is comparatively stable compared to the past year. Total Cash From Financing Activities is likely to gain to about 121.3 M in 2024, whereas Stock Based Compensation is likely to drop slightly above 31.7 M in 2024.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Coherus BioSciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Coherus BioSciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from Coherus BioSciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Coherus BioSciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.At this time, Coherus BioSciences' Change In Cash is comparatively stable compared to the past year. Total Cash From Financing Activities is likely to gain to about 121.3 M in 2024, whereas Stock Based Compensation is likely to drop slightly above 31.7 M in 2024.

Coherus BioSciences cash flow statement Correlations

-0.08-0.570.00.41-0.15-0.52-0.27-0.180.72-0.02-0.290.55-0.250.140.05-0.460.39-0.090.05-0.16-0.040.83
-0.08-0.240.670.06-0.51-0.2-0.50.38-0.290.720.460.080.42-0.170.74-0.080.70.020.44-0.360.130.12
-0.57-0.24-0.38-0.390.740.960.590.14-0.23-0.470.54-0.320.01-0.05-0.350.81-0.540.35-0.180.59-0.36-0.68
0.00.67-0.380.34-0.22-0.48-0.120.220.060.790.4-0.03-0.03-0.140.55-0.330.790.430.7-0.070.57-0.05
0.410.06-0.390.34-0.07-0.480.03-0.450.39-0.17-0.020.390.050.24-0.02-0.130.20.370.390.110.750.45
-0.15-0.510.74-0.22-0.070.60.82-0.010.34-0.510.51-0.13-0.410.23-0.410.53-0.380.54-0.110.78-0.17-0.53
-0.52-0.20.96-0.48-0.480.60.420.25-0.32-0.450.44-0.210.08-0.17-0.330.85-0.530.21-0.190.43-0.45-0.59
-0.27-0.50.59-0.120.030.820.42-0.280.04-0.510.36-0.43-0.040.38-0.660.29-0.540.62-0.190.960.01-0.54
-0.180.380.140.22-0.45-0.010.25-0.28-0.20.510.330.27-0.24-0.460.330.320.430.130.51-0.28-0.09-0.31
0.72-0.29-0.230.060.390.34-0.320.04-0.2-0.1-0.010.36-0.730.210.12-0.280.330.090.040.050.030.43
-0.020.72-0.470.79-0.17-0.51-0.45-0.510.51-0.10.15-0.02-0.08-0.360.74-0.430.84-0.050.51-0.50.180.01
-0.290.460.540.4-0.020.510.440.360.33-0.010.15-0.090.070.090.290.490.230.560.270.47-0.06-0.47
0.550.08-0.32-0.030.39-0.13-0.21-0.430.270.36-0.02-0.09-0.18-0.190.220.160.31-0.090.38-0.370.170.52
-0.250.420.01-0.030.05-0.410.08-0.04-0.24-0.73-0.080.07-0.180.11-0.090.1-0.25-0.08-0.180.08-0.040.06
0.14-0.17-0.05-0.140.240.23-0.170.38-0.460.21-0.360.09-0.190.11-0.08-0.17-0.25-0.07-0.540.34-0.120.11
0.050.74-0.350.55-0.02-0.41-0.33-0.660.330.120.740.290.22-0.09-0.08-0.190.75-0.320.24-0.63-0.010.18
-0.46-0.080.81-0.33-0.130.530.850.290.32-0.28-0.430.490.160.1-0.17-0.19-0.40.330.120.32-0.1-0.52
0.390.7-0.540.790.2-0.38-0.53-0.540.430.330.840.230.31-0.25-0.250.75-0.40.10.63-0.450.260.34
-0.090.020.350.430.370.540.210.620.130.09-0.050.56-0.09-0.08-0.07-0.320.330.10.610.70.5-0.39
0.050.44-0.180.70.39-0.11-0.19-0.190.510.040.510.270.38-0.18-0.540.240.120.630.61-0.120.7-0.06
-0.16-0.360.59-0.070.110.780.430.96-0.280.05-0.50.47-0.370.080.34-0.630.32-0.450.7-0.12-0.01-0.43
-0.040.13-0.360.570.75-0.17-0.450.01-0.090.030.18-0.060.17-0.04-0.12-0.01-0.10.260.50.7-0.010.01
0.830.12-0.68-0.050.45-0.53-0.59-0.54-0.310.430.01-0.470.520.060.110.18-0.520.34-0.39-0.06-0.430.01
Click cells to compare fundamentals

Coherus BioSciences Account Relationship Matchups

Coherus BioSciences cash flow statement Accounts

201920202021202220232024 (projected)
Change To Inventory(48.2M)(36.2M)(6.3M)(47.3M)(46.7M)(44.4M)
Change In Cash104.7M363.7M(124.0M)(353.6M)39.4M41.3M
Stock Based Compensation33.6M38.2M51.4M50.7M43.1M31.7M
Free Cash Flow15.5M147.1M(38.7M)(243.2M)(175.2M)(166.4M)
Change In Working Capital(113.9M)(32.5M)42.4M(79.3M)(36.8M)(35.0M)
Begin Period Cash Flow73.2M177.9M541.6M417.6M64.0M60.8M
Other Cashflows From Financing Activities227.1M1.8M11.0M(2.0M)(2.1M)(2.0M)
Depreciation3.3M2.9M3.5M3.7M3.8M2.7M
Other Non Cash Items15.7M6.0M143.1M75.5M52.9M30.8M
Capital Expenditures12.9M7.1M1.3M2.0M286K271.7K
Total Cash From Operating Activities28.4M154.1M(37.4M)(241.1M)(174.9M)(166.1M)
Change To Account Receivables(142.0M)(15.2M)34.1M13.1M(150.7M)(143.1M)
Net Income89.8M132.2M(287.1M)(291.8M)(237.9M)(226.0M)
Total Cash From Financing Activities89.4M223.9M51.9M54.3M69.6M121.3M
End Period Cash Flow177.9M541.6M417.6M64.0M103.3M182.6M
Sale Purchase Of Stock(815K)(880K)(1.8M)(3.7M)(3.6M)(3.4M)
Investments165K155K(1.1M)(127.4M)144.6M151.9M
Total Cashflows From Investing Activities(12.7M)(14.4M)(138.4M)(166.9M)(150.2M)(142.7M)
Cash And Cash Equivalents Changes105.0M363.7M(124.0M)(353.6M)(318.3M)(302.4M)
Cash Flows Other Operating58.8M29.0M134.8M(5.4M)(6.2M)(5.9M)
Change To Operating Activities66.4M28.7M13.7M(40.4M)(36.4M)(34.6M)
Change To Netincome34.2M38.2M249.7M83.0M95.4M68.6M
Change To Liabilities30.3M2.8M18.6M(2.8M)(3.2M)(3.0M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.